5月14日,马萨诸塞州剑桥,GSK和Boston Pharmaceuticals宣布已达成一项协议,根据该协议,GSK(葛兰素史克)将以20亿美元(包括12亿美元首付款)总金额收购Boston Pharmaceuticals主要资产efimosfermin alfa。Boston Pharmaceuticals是一家领先的临床阶段生物制药公司,为严重肝病患者开发高度靶向疗法。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.